Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Mike Polark | Wolfe Research | 19 questions · 11% challenging |
| Jason Bednar | Piper Sandler | 16 questions · 0% challenging |
| Brett Fishbin | KeyBanc Capital Markets | 15 questions · 0% challenging |
| Mike Matson | Needham | 15 questions · 0% challenging |
| Patrick Wood | UBS | 12 questions · 0% challenging |
| Mac Etoch | Stephens | 10 questions · 0% challenging |
| Dave Turkaly | Citizens JMP Securities | 5 questions · 0% challenging |
| Jacob Johnson | Stephens | 4 questions · 25% challenging |
| Dave Windley | Jefferies | 4 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wolfe Research | 1 analyst | 19 questions · 11% challenging |
| Piper Sandler | 1 analyst | 16 questions · 0% challenging |
| KeyBanc Capital Markets | 1 analyst | 15 questions · 0% challenging |
| Needham | 1 analyst | 15 questions · 0% challenging |
| Stephens | 2 analysts | 14 questions · 7% challenging |
| UBS | 1 analyst | 12 questions · 0% challenging |
| Citizens JMP Securities | 1 analyst | 5 questions · 0% challenging |
| Jefferies | 1 analyst | 4 questions · 0% challenging |
STERIS delivered a record fiscal year with $6 billion in revenue and $1 billion in net income, introducing FY2027 guidance of $11.10-$11.30 EPS implying 9-11% growth on 6-7% organic revenue expansion. Q4 revenue grew 7% with adjusted EPS up 3% to $2.83 as tariff headwinds pressured margins by 80 basis points and AST softened from weather and MedTech inventory pullbacks. Free cash flow reached an exceptional $982.9 million while strategic manufacturing and AI investments were positioned to drive FY2027 acceleration.
Demand | Revenue Growth | Trade Tariffs | Regulation Policy | Capital Allocation | Guidance Reliability | Margin | Competitive Dynamics | |
|---|---|---|---|---|---|---|---|---|
| 2025Q2 | 3 | 6 | 1 | 2 | 1 | 2 | 1 | |
| 2025Q3 | 7 | 6 | 1 | 3 | 1 | 1 | 1 | |
| 2025Q4 | 4 | 5 | 4 | 1 | 2 | 1 | 1 | 1 |
| 2026Q1 | 6 | 2 | 1 | 3 | 2 | 1 | 1 | |
| 2026Q2 | 5 | 5 | 1 | 1 | 2 | 1 | 1 | |
| 2026Q3 | 4 | 5 | 4 | 1 | 2 | 5 | 1 | 2 |
| 2026Q4 | 6 | 4 | 3 | 2 | 2 | 3 | 1 |
| '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | '26Q4 | |
|---|---|---|---|---|---|---|---|
| Demand | 3 | 7 | 4 | 6 | 5 | 4 | 6 |
| Revenue Growth | 6 | 6 | 5 | 2 | 5 | 5 | 4 |
| Trade Tariffs | 1 | 1 | 4 | 1 | 1 | 4 | 3 |
| Regulation Policy | 2 | 3 | 1 | 3 | 1 | 2 | |
| Capital Allocation | 1 | 2 | 2 | 1 | 2 | 2 | |
| Guidance Reliability | 1 | 1 | 1 | 2 | 5 | ||
| Margin | 2 | 1 | 1 | 1 | 1 | 3 | |
| Competitive Dynamics | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
On August 5, 2026, STERIS plc announced a targeted Consolidation Plan to move existing manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina, including the anticipated closure of facilities in St. Louis, Missouri and Plymouth, Minnesota. Total pre-tax restructuring charges are expected to be approximately $55 million to $70 million, roughly $40 million to $50 million of it cash, with completion anticipated during fiscal 2030.
What each event means for STE’s sentiment score is part of Tellvest Pro.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q2 | $1.33B | +7.3% | $1.51 | +30.2% | 43.6% | 16.5% | 11.3% | $149M |
| FY2025 Q3 | $1.37B | +5.6% | $1.75 | +23.2% | 44.5% | 17.9% | 12.7% | $244M |
| FY2025 Q4 | $1.48B | +4.0% | $1.48 | +10747.5% | 43.3% | 14.6% | 9.8% | $190M |
| FY2026 Q1 | $1.39B | +8.7% | $1.79 | +22.6% | 45.1% | 17.7% | 12.8% | $326M |
| FY2026 Q2 | $1.46B | +9.9% | $1.94 | +28.5% | 44.2% | 18.4% | 13.1% | $201M |
| FY2026 Q3 | $1.50B | +9.2% | $1.96 | +12.0% | 43.8% | 18.1% | 12.9% | $200M |
| FY2026 Q4Selected | $1.59B | +7.3% | $2.24 | +51.4% | 43.9% | 19.9% | 13.9% | $245M |
| FY2027 Q1 | $1.49B | +7.3% | $2.04 | +14.0% | 45.8% | 19.1% | 13.4% | $280M |
| Year | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2023 | $4.96B | +8.1% | $1.07 | -55.2% | 43.6% | 5.4% | 2.2% | $395M |
| FY2024 | $4.84B | -2.5% | $3.82 | +256.6% | 43.1% | 17.8% | 7.8% | $613M |
| FY2025 | $5.46B | +12.9% | $6.20 | +62.5% | 44.0% | 15.9% | 11.3% | $778M |
| FY2026Selected | $5.94B | +8.7% | $7.93 | +27.9% | 44.2% | 18.6% | 13.2% | $972M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call May 12, 2026
FY2026 Q4 in brief
STERIS delivered a record fiscal year with $6 billion in revenue and $1 billion in net income, introducing FY2027 guidance of $11.10-$11.30 EPS implying 9-11% growth on 6-7% organic revenue expansion.
Newest quarter FY2027 Q1 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Steris (STE), FY2026 Q4: 7/10. Scores: Steris’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: STE daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
GAAP revenue YoY +7.29% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
STE Steris | 7 | +7.3% | |
| ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| EW Edwards Lifesciences | 9 | +16.7% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| SYK Stryker Corporation | 4 | +2.6% | |
| ZBH Zimmer Biomet | 9 | +9.3% |